SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Yang Ming

(Last) (First) (Middle)
18TH FLOOR, JIALONG INTERNATIONAL
BUILDING, 19 CHAOYANG PARK ROAD

(Street)
BEIJING F4 100125

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
China Biologic Products, Inc. [ CBPO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/14/2015
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 09/14/2015 M (1) 1,000 (1) A $9.85 36,086 D
Common stock 09/14/2015 S (2) 11,304 (2) D $97.08 (4) 24,782 D
Common stock 09/15/2015 M (3) 9,000 (3) A $9.85 33,782 D
Common stock 09/15/2015 S (3) 9,000 (3) D $94.56 (5) 24,782 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (6) $9.85 09/14/2015 M 1,000 09/01/2013 08/31/2022 Common stock 1,000 (6) 49,000 (8) D
Stock Option (right to buy) (7) $9.85 09/15/2015 M 9,000 09/01/2013 08/31/2022 Common stock 9,000 (7) 40,000 (8) D
Explanation of Responses:
1. Represents 1,000 shares of common stock acquired by the Reporting Person through the exercise of stock options to purchase the Issuer's common stock. See Footnote 6 below for further details on the relevant stock options.
2. Represents 11,304 shares of common stock (the "September 14 Sold Common Stock") sold on the open market at a weighted average price of $97.08 per share on September 14, 2015. The September 14 Sold Common Stock was acquired by the Reporting Person through the exercise of stock options to purchase 1,000 shares of the Issuer's common stock and vesting of 10,304 restricted stocks.
3. Represents 9,000 shares of common stock (the "September 15 Sold Common Stock") sold on the open market at a weighted average price of $94.56 per share on September 15, 2015. The September 15 Sold Common Stock was acquired by the Reporting Person through the exercise of stock options to purchase 9,000 shares of the Issuer's common stock. See Footnote 7 below for further details on the relevant stock options.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in the open market at prices ranging from $93.70 to $100.50, inclusive. The Reporting Person undertakes to provide to any security holders of China Biologic Products, Inc. (the "Issuer") or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Footnote 4 and Footnote 5 to this Form 4.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in the open market at prices ranging from $94.00 to $95.54, inclusive.
6. Represents previously reported stock options to purchase 1,000 shares of the Issuer's common stock, granted to the Reporting Person under the Issuer's 2008 equity incentive plan, pursuant to a stock option agreement dated August 31, 2012. The options were scheduled to vest in four equal portions on a quarterly basis over a four-year period, with the initial vesting date being September 1, 2013, provided that the Reporting Person is employed by the Issuer on each vesting date.
7. Represents previously reported stock options to purchase 9,000 shares of the Issuer's common stock, granted to the Reporting Person under the Issuer's 2008 equity incentive plan, pursuant to a stock option agreement dated August 31, 2012. The options were scheduled to vest in four equal portions on a quarterly basis over a four-year period, with the initial vesting date being September 1, 2013, provided that the Reporting Person is employed by the Issuer on each vesting date.
8. Includes the balance of the previously reported stock options to purchase 50,000 shares of the Issuer's common stock, granted to the Reporting Person under the Issuer's 2008 equity incentive plan, pursuant to a stock option agreement dated August 31, 2012.
/s/ Ming Yang 09/16/2015
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.